Double attack on aggressive lung cancer: radiation joins forces with immune drug
NCT ID NCT04472949
Summary
This trial is testing if adding chest radiation therapy to a maintenance immunotherapy drug (durvalumab) can better control advanced small cell lung cancer. Patients first receive standard chemotherapy combined with durvalumab. If the cancer responds or stays stable, they then receive radiation to the chest while continuing the immunotherapy for up to two years. The main goal is to see if this combination helps keep the cancer from progressing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HFR Freiburg - Kantonsspital
Villars-sur-Glâne, 1752, Switzerland
-
Hôpitaux Universitaires de Genève
Geneva, 1211, Switzerland
-
IOSI Ospedale Regionale di Bellinzona e Valli
Bellinzona, 6500, Switzerland
-
Inselspital Bern
Bern, 3010, Switzerland
-
Kantonsspital - St. Gallen
Sankt Gallen, CH-9007, Switzerland
-
Kantonsspital Aarau
Aarau, CH-5001, Switzerland
-
Kantonsspital Graubuenden
Chur, CH-7000, Switzerland
-
Kantonsspital Olten
Olten, CH-4600, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
Klinik Hirslanden
Männedorf, 8708, Switzerland
-
Regionalspital Thun
Thun, 3600, Switzerland
-
Spital Männedorf
Männedorf, 8708, Switzerland
-
Universitaetsspital Basel
Basel, 4031, Switzerland
-
UniversitätsSpital Zürich
Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.